Trastuzumab Withdrawn Phase 1 / 2 Trials for Cognitive/Functional Effects / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Psychosocial Effects of Cancer and Its Treatment / Cancer, Breast Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1 / 2
clinicaltrials.gov IdentifierTitleDrugs
NCT02569489Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer